Advanced or Recurrent Solid Tumors
5 clinical trials · Condition
◉ Watch Advanced or Recurrent Solid Tumors
| Record | Firm | Date |
|---|---|---|
| Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors (NCT01286987) | Pfizer | 2011-01-03 |
| Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors (NCT01285453) | Novartis Pharmaceuticals | 2009-03-01 |
Track Advanced or Recurrent Solid Tumors automatically
Every clearance here is in the API, with alerts when new ones post.